Tirzepatide vs Retatrutide: Dual vs Triple Agonist Comparison

The development of incretin-based therapies for obesity represents one of medicine's most significant advances. The progression from single to dual to triple agonism illustrates how each generation builds upon its predecessor:

First Generation — Single GLP-1 Agonists: Liraglutide (Saxenda, 2014) and semaglutide (Wegovy, 2021) target the GLP-1 receptor alone. Semaglutide achieves approximately 15–17% body weight reduction — far exceeding any previous pharmacological obesity treatment.

Second Generation — Dual GLP-1/GIP Agonists: Tirzepatide (Mounjaro/Zepbound, Eli Lilly) adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism to GLP-1 agonism. This dual mechanism achieves approximately 20–26% weight loss in clinical trials — substantially more than GLP-1 alone.

Third Generation — Triple Agonists: Retatrutide (Eli Lilly) adds glucagon receptor agonism to the GLP-1/GIP backbone, creating a triple agonist. Phase 2 data showed up to 24% weight loss at 48 weeks, with Phase 3 results expected in 2026.

This progression demonstrates a consistent pattern: each additional receptor target adds incremental weight loss efficacy, but also introduces additional complexity in terms of mechanism, dosing, and side effects.

Tirzepatide is a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. It is the first-in-class dual incretin agonist, approved as Mounjaro for type 2 diabetes and as Zepbound for obesity.

Mechanism of Action: - GLP-1 receptor agonism: Reduces appetite, slows gastric emptying, improves glucose-stimulated insulin secretion - GIP receptor agonism: The role of GIP in weight management was initially counterintuitive — GIP was considered obesogenic. However, pharmacological GIP agonism at high doses appears to synergise with GLP-1 effects on appetite and energy expenditure. The exact mechanism remains an active area of research.

Clinical Data (Key Trials): - SURMOUNT-1 (obesity without diabetes): 15mg tirzepatide achieved 22.5% mean weight loss at 72 weeks vs. 2.4% with placebo - SURMOUNT-2 (obesity with diabetes): 15mg achieved 14.7% weight loss at 72 weeks - SURPASS Programme (diabetes): Superior HbA1c reduction and weight loss compared to insulin, semaglutide, and other diabetes medications

Strengths: - Unprecedented weight loss efficacy for a pharmaceutical agent - Significant improvements in cardiometabolic markers (blood pressure, lipids, liver fat, inflammatory markers) - Once-weekly injection - FDA and EMA approved with extensive safety data - Demonstrated cardiovascular benefits in the SELECT-2 trial

Limitations: - Gastrointestinal side effects (nausea, diarrhoea) affect 15–30% of patients - Weight regain upon discontinuation (67% of lost weight regained within 1 year in studies) - High cost (approximately £850–1,000/month without insurance in the UK) - Supply constraints have limited availability in some markets

Retatrutide is a 39-amino-acid peptide that activates three receptors: GLP-1, GIP, and glucagon receptors. It is currently in Phase 3 clinical development by Eli Lilly.

The Glucagon Receptor Addition: The key differentiator is glucagon receptor agonism. Glucagon is traditionally associated with raising blood sugar — so its inclusion in a diabetes/obesity drug seems paradoxical. However, glucagon has several metabolic effects that are beneficial for weight management: - Increases energy expenditure (thermogenesis) - Promotes hepatic lipid oxidation (liver fat burning) - Reduces food intake through central mechanisms - Increases satiety through GI effects

The challenge is balancing glucagon's glucose-raising effect against the glucose-lowering effects of GLP-1 and GIP agonism. In retatrutide, the GLP-1 and GIP components appear to sufficiently counteract glucagon's hyperglycaemic potential.

Phase 2 Data (The Study That Made Headlines): - 12mg retatrutide achieved 24.2% mean weight loss at 48 weeks - 58% of participants lost ≥25% of body weight - Up to 17% of participants lost ≥30% of body weight — approaching bariatric surgery outcomes - Significant reductions in liver fat (up to 86% reduction in MASLD/NASH patients) - HbA1c reductions comparable to tirzepatide

Phase 3 Programme: The TRIUMPH programme (multiple Phase 3 trials) is underway with results expected throughout 2026. These larger trials will confirm whether Phase 2 results hold in broader patient populations.

Safety Signals: - GI side effects similar in profile to GLP-1 agonists (nausea, diarrhoea, vomiting) - No concerning hepatotoxicity signals despite glucagon's hepatic effects - Heart rate increases observed (likely glucagon-mediated) — being monitored in Phase 3 - Longer-term safety data pending

Direct Comparison (based on available data — no head-to-head trial yet):

| Parameter | Tirzepatide (15mg) | Retatrutide (12mg) | |-----------|-------------------|-------------------| | Receptors | GLP-1, GIP | GLP-1, GIP, Glucagon | | Weight Loss | ~22.5% (72 wk) | ~24.2% (48 wk) | | ≥20% Weight Loss | ~57% of patients | ~71% of patients | | HbA1c Reduction | -2.1% to -2.4% | -1.7% to -2.2% | | Liver Fat Reduction | ~50% | Up to 86% | | Approval Status | Approved (2022-23) | Phase 3 (2026) | | Dosing | Once weekly | Once weekly |

Key Differences: - Retatrutide's glucagon component provides additional energy expenditure and liver fat reduction - Tirzepatide has proven long-term safety data and regulatory approval - Retatrutide's Phase 2 data suggests potentially superior weight loss, but Phase 3 confirmation is needed - The liver fat reduction with retatrutide is particularly notable for MASLD/NASH patients

What Comes Next?: - Quadruple agonists: Research into four-receptor agonists is already underway - Oral formulations: Both companies are developing oral versions of their multi-agonist peptides - Combination with other approaches: Amylin analogues, myostatin inhibitors, and other agents may be combined with incretin agonists - Muscle-sparing formulations: Addressing the concern that weight loss includes lean mass loss

The Broader Context: The incretin agonist revolution is transforming how we think about obesity treatment. Weight loss of 20–25%+ with a weekly injection approaches the efficacy of bariatric surgery — without the surgical risk. However, questions about long-term safety, weight maintenance, cost, and equitable access remain.

Disclaimer: This article is for educational purposes only. Tirzepatide and retatrutide are prescription medications (tirzepatide) or investigational compounds (retatrutide) that should only be used under medical supervision. This is not medical advice. Consult your healthcare provider for weight management guidance.